Please login to the form below

Not currently logged in
Email:
Password:

BARDA to support GSK's antibiotic research

GSK and BARDA have agreed a contract supporting GSK's development of a potential novel antibiotic against hospital Gram negative and biothreat pathogens

GlaxoSmithKline (GSK) and the Biomedical Advanced Research and Development Authority (BARDA) have agreed a contract which will support GSK's development of a potential novel antibiotic against hospital Gram negative and biothreat pathogens.

Initially, GSK will receive a $38.5m award from BARDA, a division in the US Department of Health and Human Services, over two years. This award will not only contribute to existing studies, but also new research into various biothreat pathogens; such as Yersinia pestis, the cause of bubonic plague, and Bacillus anthracis, the cause of anthrax.

Specifically, the award will be used to contribute to the development of GSK2251052, an experimental antibiotic, against the bacterial enzyme leucyl tRNA synthetase.

GSK welcomed the agreement with BARDA, which acts as part of BARDA's effort to support the "advanced development of countermeasures that address emerging disease threats and public health".

If BARDA follows the options for future funding, it may bring the total value of the award to $94.5m.

7th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rock Unlimited

Rock Unlimited: Science as you've never seen it...

Latest intelligence

How do you solve a problem like non-adherence? Part 2
Following her previous piece on patient medical non-adherence, Head of Customer Experience Elisa del Galdo takes a look at the different patient personas that emerge during the diagnosis and treatment...
The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...

Infographics